A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
AbbVie Inc.
ABBV
$460.0B
Mkt Cap
$259.36
+0.95%
AbbVie Inc. (ABBV) has a current P/E ratio of 109.9, compared to its historical median P/E of 21.3. The stock is currently considered Expensive based on its historical valuation range.
AbbVie Inc. (ABBV) has a 5-year average return on invested capital (ROIC) of 17.0%. This indicates strong capital allocation and a potential competitive advantage.
AbbVie Inc. (ABBV) has a market capitalization of $478.2B. It is classified as a mega-cap stock.
Yes, AbbVie Inc. (ABBV) pays a dividend with a trailing twelve-month yield of 2.47%. The company also returns capital through share buybacks, with a buyback yield of 0.32%.
Based on historical P/E analysis, AbbVie Inc. (ABBV) appears expensive. The current P/E of 109.9 is 416% above its historical median of 21.3. The estimated fair value CAGR (P/E method) is -7.3%.
AbbVie Inc. (ABBV) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AbbVie Inc. (ABBV) reported annual revenue of $61.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
AbbVie is a global, diversified research-based biopharmaceutical company with a comprehensive product portfolio spanning immunology, neuroscience, oncology, aesthetics, and eye care. The company operates as a single global business segment focused on the research, development, manufacturing, and commercialization of innovative medicines addressing complex and serious diseases. In immunology, AbbVie maintains extensive portfolios across rheumatology, dermatology, and gastroenterology with flagship products including Skyrizi (IL-23 inhibitor), Rinvoq (JAK inhibitor), and Humira (TNF inhibitor), which address unmet needs in autoimmune diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The neuroscience franchise encompasses psychiatric and neurological treatments including Vraylar (dopamine D3-preferring partial agonist), Botox Therapeutic (neuromuscular blocking agent), migraine therapies Ubrelvy and Qulipta (CGRP receptor antagonists), and Parkinson's disease treatments Vyalev and Duodopa (levodopa-based therapies). The oncology portfolio targets difficult-to-treat cancers with products including Imbruvica (BTK inhibitor), Venclexta (BCL-2 inhibitor), and newer antibody-drug conjugates such as Elahere and Epkinly. The aesthetics segment holds market-leading positions globally with Botox Cosmetic, the Juvederm Collection of dermal fillers, and complementary products including CoolSculpting and SkinMedica skincare. Eye care products address vision preservation with Ozurdex (corticosteroid implant) and glaucoma treatments Lumigan and Ganfort. The company's commercial organization coordinates marketing, sales, and distribution by geographic region and therapeutic area, supported by a global research and development and supply chain infrastructure.
【Strong portfolio momentum continuing】 Management expects AbbVie to deliver top-tier performance in 2026 with total sales growth of 9.5%, driven primarily by continued robust growth from Skyrizi and Rinvoq, which are anticipated to generate combined sales exceeding $31 billion. The company anticipates substantial sales ramps for Vyalev in Parkinson's disease, achieving blockbuster status, and continued double-digit revenue growth from leading migraine products. Multiple pipeline catalysts are expected throughout 2026 and into 2027, including pivotal data for additional Rinvoq indications, initial data from Crohn's combination platform studies, key readouts for next-generation neuroscience assets, and registrational data for oncology programs such as Etentamig and Temab-A across multiple solid tumors. Management remains confident in delivering high single-digit revenue growth through 2029 despite ongoing headwinds from Humira biosimilar erosion and Imbruvica IRA pricing impacts. The company is actively expanding its field sales team to support anticipated demand growth, particularly in the emerging Parkinson's disease franchise, and continues to invest substantially in early and mid-stage programs with potential to drive growth in the next decade.
| Metric | Target | Period |
|---|---|---|
| Total net revenues | approximately $67.3 billion | FY2026 |
| Adjusted earnings per share | $14.08 to $14.28 | FY2026 |
| Skyrizi global revenues | $21.6 billion | FY2026 |
| Rinvoq global sales | $10.2 billion | FY2026 |
| Adjusted gross margin | above 84% of sales | FY2026 |
| Adjusted operating margin ratio | approximately 47.5% of sales | FY2026 |
| Adjusted net interest expense | approximately $2.7 billion | FY2026 |
Total net revenues (FY2026): “We now expect total net revenues of approximately $67.3 billion, an increase of $300 million.”
Adjusted earnings per share (FY2026): “we are raising our full-year adjusted earnings per share guidance to between $14.08 and $14.28.”
Skyrizi global revenues (FY2026): “We now expect SKYRIZI global revenues of $21.6 billion, an increase of $100 million, reflecting demand growth in psoriatic and IBD indications.”
Rinvoq global sales (FY2026): “RINVOQ global sales of $10.2 billion, an increase of $100 million, reflecting strong performance in the rheum and gastro indications.”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 62.8B | 61.2B | 56.3B | 54.3B | 58.1B | 56.2B |
| Net Income | 3.6B | 4.2B | 4.2B | 4.8B | 11.8B | 11.5B |
| EPS | $1.95 | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Free Cash Flow | 20.0B | 17.8B | 17.8B | 22.1B | 24.2B | 22.0B |
| ROIC | 16.4% | 15.5% | 14.9% | 15.4% | 20.6% | 18.3% |
| Gross Margin | - | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% |
| Debt/Equity | 0.00 | -20.91 | 20.46 | 5.82 | 3.72 | 5.03 |
| Dividends/Share | $6.41 | $6.65 | $6.29 | $5.99 | $5.71 | $5.31 |
| Operating Income | 15.3B | 15.1B | 9.1B | 12.8B | 18.1B | 17.9B |
| Operating Margin | 24.4% | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| ROE | 0.0% | - | 61.9% | 34.9% | 72.1% | 80.5% |
| Shares Outstanding | 1,844M | 1,774M | 1,773M | 1,772M | 1,777M | 1,778M |
AbbVie Inc. passes 5 of 9 quality checks, suggesting mixed fundamentals.
AbbVie Inc. trades at 109.9x trailing earnings, compared to its 15-year median P/E of 21.3x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 25.7x vs a median of 10.5x. The company's 5-year average ROIC is 17.0% with a gross margin of 68.3%. Total shareholder yield (dividends + buybacks) is 2.8%. At current prices, the estimated annualized return to fair value is +4.2%.
AbbVie Inc. (ABBV) has a net profit margin of 6.8%. This is a modest margin.
AbbVie Inc. (ABBV) generated $17.8 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
AbbVie Inc. (ABBV) reported earnings per share (EPS) of $2.36 in its most recent fiscal year.
AbbVie Inc. (ABBV) has a 5-year average gross margin of 68.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for AbbVie Inc. (ABBV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AbbVie Inc. (ABBV) has a book value per share of $-1.84, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects AbbVie to deliver top-tier performance in 2026 with total sales growth of 9.5%, driven primarily by continued robust growth from Skyrizi and Rinvoq, which are anticipated to generate combined sales exceeding $31 billion. The company anticipates substantial sales ramps for Vyalev in Parkinson's disease, achieving blockbuster status, and continued double-digit revenue growth from leading migraine products. Multiple pipeline catalysts are expected throughout 2026 and into 2027, including pivotal data for additional Rinvoq indications, initial data from Crohn's combination platform studies, key readouts for next-generation neuroscience assets, and registrational data for oncology programs such as Etentamig and Temab-A across multiple solid tumors. Management remains confident in delivering high single-digit revenue growth through 2029 despite ongoing headwinds from Humira biosimilar erosion and Imbruvica IRA pricing impacts. The company is actively expanding its field sales team to support anticipated demand growth, particularly in the emerging Parkinson's disease franchise, and continues to invest substantially in early and mid-stage programs with potential to drive growth in the next decade.
Based on recent SEC filings and earnings calls, AbbVie Inc. (ABBV) has provided the following forward guidance: Total net revenues: approximately $67.3 billion (FY2026); Adjusted earnings per share: $14.08 to $14.28 (FY2026); Skyrizi global revenues: $21.6 billion (FY2026); Rinvoq global sales: $10.2 billion (FY2026); Adjusted gross margin: above 84% of sales (FY2026), plus 2 additional metrics.
Adjusted gross margin (FY2026): “we continue to forecast full-year adjusted gross margin above 84% of sales”
Adjusted operating margin ratio (FY2026): “We now anticipate an adjusted operating margin ratio of approximately 47.5% of sales”
Adjusted net interest expense (FY2026): “We also now expect adjusted net interest expense of approximately $2.7 billion, a reduction of $100 million”